GS-2

GS-2 is a preclinical-stage broad-spectrum antimicrobial agent being developed by Wintermute Biomedical. It is part of the company's "GS" platform, which utilizes proprietary fatty acid-based formulations to disrupt microbial cell membranes. Unlike the company's lead candidate GS-1, which is targeted for clinical applications such as sepsis and skin infections, GS-2 is specifically designed for environmental microbial control. The agent is intended to combat a wide range of pathogens, including multi-drug resistant (MDR) bacteria, by employing a physical mechanism of action that makes the development of microbial resistance significantly more difficult compared to traditional antibiotics.